Prenatal paraben exposure and atopic dermatitis-related outcomes among children

Loreen Thürmann1, Gunda Herberth2, Bettina Seiwert3

  • 1Molecular Epidemiology Unit, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, associated partner of the German Center for Lung Research (DZL), Berlin, Germany.

Allergy
|May 2, 2021
PubMed

Insights

Prenatal exposure to ethylparaben (EtP) and n-butylparaben (nBuP) may increase children's risk of developing persistent atopic dermatitis (AD) early in life, especially in those without maternal AD history.

Area of Science:

  • Environmental Health
  • Dermatology
  • Pediatrics

Background:

  • Parabens are common preservatives in consumer products.
  • Concerns exist regarding potential health effects of prenatal paraben exposure.
  • Previous studies linked prenatal exposure to increased asthma risk.

Purpose of the Study:

  • To investigate the association between prenatal paraben exposure and the risk of childhood atopic dermatitis (AD).
  • To explore different AD phenotypes and their relationship with specific paraben exposures.

Main Methods:

  • Analysis of 261 mother-child pairs from the German LINA study.
  • Quantification of eight paraben species in maternal urine during gestational week 34.
  • Classification of childhood AD into four phenotypes based on onset and persistence.

Main Results:

  • Prenatal exposure to ethylparaben (EtP) and n-butylparaben (nBuP) was associated with an increased risk of very early-onset AD without remission.
  • This association was more pronounced in children without a maternal history of AD.
  • The effects were independent of the child's sex.

Conclusions:

  • Prenatal exposure to EtP and nBuP may heighten susceptibility to persistent AD in early childhood.
  • Children without a genetic predisposition (maternal AD history) appear more vulnerable to these effects.
  • Findings suggest a potential role for environmental factors like parabens in AD development.
Abstract

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
508
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.6K
Types of Toxins01:36

Types of Toxins

Humans continually engage with an environment rich in potentially harmful chemicals. These are introduced to our bodies through inhalation, ingestion, or skin contact. These chemicals exist in various forms, such as air and environmental pollutants, agricultural chemicals, organic solvents, and heavy metals.
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
2.8K
Allergic Reactions02:06

Allergic Reactions

Overview
29.6K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
57